Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Golcadomide hydrochloride by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
Golcadomide hydrochloride by Bristol-Myers Squibb for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase III for Diffuse Large B-Cell Lymphoma. According...
Golcadomide hydrochloride by Bristol-Myers Squibb for Mantle Cell Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Mantle Cell Lymphoma. According to...
Golcadomide hydrochloride by Bristol-Myers Squibb for Primary CNS Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Primary CNS Lymphoma. According to...
Golcadomide hydrochloride by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...
Golcadomide hydrochloride by Bristol-Myers Squibb for Follicular Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Follicular Lymphoma. According to GlobalData,...